SCHEMBL12220331

SCHEMBL12220331

C=C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.53
CYP2C19 P33261 3/20 0.53
LMNA P02545 3/20 0.53
MAPT P10636 2/20 0.53
ALOX15 P16050 1/20 0.53
HTT P42858 1/20 0.53
CREBBP Q92793 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ALDH1A1 P00352 6/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
CYP3A4 P08684 1/20 0.42
KMT2A Q03164 1/20 0.42
EPHX2 P34913 1/20 0.41
BBOX1 O75936 1/20 0.40
ASPH Q12797 1/20 0.40
KDM8 Q8N371 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
HIF1AN Q9NWT6 1/20 0.40
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6232883 0.86 LMNA (0.60) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL14045645 0.81 CYP2C9 (0.53) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL407251 0.75 LMNA (0.42) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL15744622 0.74 LMNA (0.53) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL9749762 0.74 LMNA (0.53) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL12588788 0.74 LMNA (0.53) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL5633728 0.74 LMNA (0.49) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL3422430 0.73 CYP2C9 (0.47) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL3420466 0.73 CYP2C9 (0.47) CYP2C9CYP2C19LMNAMAPTALOX15
SCHEMBL25827593 0.70 CYP2C9 (0.44) CYP2C9CYP2C19LMNAMAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039532-B2 Heterocyclic compound, ultraviolet absorbent and composition containing the same FUJIFILM CORPORATION (JP) 2011-10-18 US disclosed
US-20100210762-A1 HETEROCYCLIC COMPOUND, ULTRAVIOLET ABSORBENT AND COMPOSITION CONTAINING THE SAME FUJIFILM CORPORATION (JP) 2010-08-19 US disclosed
US-20100130638-A1 ULTRAVIOLET ABSORBENT COMPOSITION FUJIFILM CORPORATION (JP) 2010-05-27 US disclosed
US-20100025642-A1 ULTRAVIOLET ABSORBENT COMPOSITION FUJIFILM CORPORATION (JP) 2010-02-04 US disclosed
US-20090240067-A1 METHOD OF PRODUCING A BISBENZODITHIOL COMPOUND FUJIFILM CORPORATION (JP) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210762-A1 HETEROCYCLIC COMPOUND, ULTRAVIOLET ABSORBENT AND COMPOSITION CONTAINING THE SAME F12, F2, CYP24A1 CYP2C9 553/4885CYP2C19 488/4885LMNA 2510/4885
US-20090240067-A1 METHOD OF PRODUCING A BISBENZODITHIOL COMPOUND SQOR, NQO1, PBRM1 CYP2C9 175/4885CYP2C19 218/4885LMNA 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.